FLT3 and acute myeloid leukemia: To date, several potential FLT3 inhibitors have been developed and examined in AML patients, including lestaurtinib (CEP701) and midostaurin (PKC412) in phase III clinical trials and sunitinib malate (Sutent), sorafenib (Nexavar), quizartinib (AC220), and crenolanib (CP-868596) in phase II trials.